Biolex presents Locteron US Phase 2a hepatitis C data at EASL
Friday, April 24, 2009 - 09:42
in Health & Medicine
Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron(R) will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark.